[Taiwell-KY] Announcement of Completion of Capital Reduction Registration by Subsidiary Taiwan Taiwell Biotechnology Co., Ltd.

1. Date of regulatory approval for capital reduction: August 13, 115 2. Date of completion of capital change registration: August 14, 115 3. Impact on financial statements (including differences in paid-in capital and outstanding shares, and impact on net asset value per share): (1) Paid-in capital: Before reduction: NT$2,510,707,000; After reduction: NT$15,000,000. (2) Outstanding shares: Before reduction: 251,070,700 shares; After reduction: 1,500,000 shares. (3) Impact on net asset value per share: Before reduction: NT$0.25; After reduction: NT$41.61. 4. Planned share exchange program: Not applicable. 5. Number of listed common shares after capital reduction: Not applicable. 6. Ratio of listed common shares to total issued common shares after capital reduction (listed common shares after reduction / total issued common shares after reduction): Not applicable. 7. Measures to address low equity liquidity if the number of listed common shares after reduction is less than 60 million shares and less than 25%: Not applicable. 8. Other matters to be disclosed: None.